Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It's after 4PM, normally posted between 4:30 + 5:30.
That's a great question.
I have NO idea why.
I don't think they should be.
But I don't understand a lot of investors thinking and market caps.
Why is a new IPO company that makes vegi-burgers who will lose money for years before any earnings worth 4 billion market cap?
Seems crazy to me.
Thanks for the articles. When I read articles like this one, it just reinforces my belief as to why MultiTAA is so much better than CAR-T. Ziopharm, with a market cap more than double MRKR's is interesting but they are just starting their phase 1, and I'm not really worried about them taking market share from MRKR.
Thanks again.
????????? But I'm not giving up.
I think we both have the same feeling that something different (good) is starting to happen.
On 4-23 I bought for $5.07, on 4-30 I bought for $5.05.
Like I said in a previous post today, unless we miss earnings on 5-10, I just have the feeling that the buying in the low $5's is history.
Hey, I may be wrong and look foolish, but by looking at what's been happening intraday and towards the end of the day recently, I get the feeling that the slow climb and holding those gains have begun.
Having said that, I still today put in open orders at 5.17, 5.15, and 5.10 just in case.
I mean Beyond Meat BYND, losing money with no profits anytime soon goes public yesterday, valued at almost 4 billion?
Getting 80% of there pea protein from one source and all pea protein running scarce, and almost 4 billion?
Marker can cure cancers and is valued at 300 million?
I guess a vege-burger is worth 13 times more than a cancer cure?
One week from today, on May 10th, MRKR reports earnings.
Estimate is -$0.17.
If it is substantially worse than that, then you may?, possibly?, get one final chance to buy MRKR in the low 5's.
After that it should be a slow, steady, slow climb higher and higher until news (yes, even in the absence of news).
If (whenever that is) we get definitively great FDA trials news (it will come), it will jump up big as shorts will be forced to cover.
Up till now, the shorts have ruled the battlefield because every time they shorted more and more, there was NO substantial buying to reciprocate against it to act as a counterbalance.
Once we get that great FDA news and the price jumps up, YES, YES, the shorts who covered will jump back in and short at the then much higher price, BUT the difference will be, THEN there WILL BE substantial buying to reciprocate against it to act as a counterbalance, and the climb higher and higher will continue.
To anybody who has been worried about the stock price decline over the last few months, stop worrying, it was not due to fundamentals, it was due to shorters.
To anybody who got scared out and sold recently, buy back in so you're not kicking yourself is the ass come the end of 2019 and beyond, because the more beyond we go, the more you're going to be mad at yourself for selling and not holding.
I don't want to ramble, but no brainers don't come along very often.
In 1991, anybody who understood Qualcomm's CDMA technology compared to the then current TDMA or GSM technology KNEW it was a no brainer that CDMA will take over the world.
I think MRKR's MultiTAA technology versus CAR-T is a similar no brainer.
No matter what you compare it to, individual CAR-T, off the shelf CAR-T, CRISPR, RNAI, MDNA, Talon, Zinc fingers, etc., when you compare all of the positives and all of the negatives (price, risk, time, side effects, etc.) concerning all, I think MultiTAA is a no brainer that will capture a substantial share of the market for several cancer indications.
Thanks, I'm just tired of these shorters screwing us. I wish some big money would just start to buy to force a short squeeze which would make the price jump up. If we know that 3 million shares were shorted under $7 and the stock shares are illiquid, I don't think it would take much buying to get the shorts running for the hills and get MRKR's price where it belongs.
OK, now seriously.
IF, TD Ameritrade has none to short.
And Schwab has 100,000.
And Fidelity has 399,000 (as of right now - tomorrow may be less or none).
And E-trade would also have to borrow from another brokerage...
And there are currently 4 million shares short, with at most another about 1/2 million still able to be shorted.
If, IF, IF, all 1/2 million shares were shorted, that would be 4 1/2 million shares shorted …
And WE KNOW that it is A FACT that 3 1/2 million out of those 4 1/2 million shares were shorted at BELOW $7 (that's a FACT because they were all shorted since January 1st - BELOW $7).
The first bit of ANY GOOD NEWS will cause a short squeeze.
I do not see how it can be anything else.
Follow-up. Just called E-Trade. They have MRKR as "hard to borrow" which means they would borrow shares from another broker.
AND Fidelity has it as "Hard to Borrow", but they have 399,000 shares they can borrow to short.
With the 4 giants all having either hard to borrow or not available to borrow, I can't see how shorts would be able to raise substantially from it's current 4 million shares shorted mark.
Well, this is interesting.
Talked to my broker today at T. D. Ameritrade.
An Ameritrade customer is currently NOT able to short MRKR stock.
In order to short a stock, the brokerage (borrows) it from another customers account who holds those shares.
Apparently, there are SO MANY shares shorted, that there are NO MORE available to (borrow) to short.
ALSO, has anybody else noticed what has been CONSISTANTLY happening (a good 80%+) of the time in the last 5 minutes of the trading day?
What does that tell YOU??
P.S. Just for yucks, I just called Charles Schwab, they only have 100,000 shares available to short.
I think all of this should be telling us something.
Everybody has heard - SELL in May and go away.
NOT this year - Why?
2 Trillion Infrastructure (maybe).
Today's FOMC meeting - not raising rates (hopefully).
Japan 40 Billion commitment.
Japan agriculture deal coming.
China trade deal coming.
USMCA passing (unless partisans are idiots).
3.2% for the first quarter (normally the worst quarter).
Buy MRKR in May and break the short sellers sounds better to me.
To answer your question, I was referring to my previous posts where I opined on this mental algorithm that has had our stock price bouncing between $5 + $6 and how I am trying to profit from it's (almost) predictability.
I had mentioned that my next buy order was in at 5.05, and sure enough, it gets filled, and then back up we go.
These are only short term shares that I am trading, I still own and will hold a bunch of long term shares, but for trading I am just playing the game they (whoever they are) are setting up.
Next stop, sell the 5.05 buys near the mid 5's, make 1K+, wait for next drop down, rinse and repeat.
I believe it is a function of the short sellers, which has steadily increased from 1 million shares to 4 million shares since the start of 2019.
MRKR price goes up to the $5.50 to $6 range … and then the shorters jump in and short more, which brings it back down to low $5's.
AND THEN … MRKR price goes up to the $5.50 to $6 range … and then the shorters jump in and short more, which brings it back down to low $5's.
AND THEN … MRKR price goes up to the $5.50 to $6 range … and then the shorters jump in and short more, which brings it back down to low $5's.
OPINIONS PLEASE - I just saw MRKR videos upsetting to me.
WHY is Marker paying a (hype the junk company) like RedChip to do hype videos for them?
Now, everybody here knows I am all for more exposure and even encouraged it on message boards and blogs, but I get an instant bad feeling in my stomach when I see a company paying hype firms and doing hype videos.
90% of the time, companies using hype firms are garbage (that's why they are using hype firms), and it just feels bad to me.
I mean, if you are a reflection of the company you keep (company as in friends, not as in a business company), then why are we hanging out with a hyper like RedChip?
I really LOVE Markers technology and potential, so would someone (or many someones) PLEASE explain to me why I am wrong about this.
example;
Today's low - 5.05
Nice presentation on 038 and also the newer 039.
I also don't understand why, if Marker can add up to 11 antigens (from 5), and already did the pre-clinical work (they said on 3-28), why they didn't do a more targeted cocktail for pancreatic cancer.
What really perplexes me is Marker as a stock, and it's current stock price, (you mentioned buying 10 or 20 shares).
You mention ALLO with a market cap of 3.6 billion and a pipeline that is mostly pre-clinical (behind Markers).
And FATE with a market cap of 1.1 billion and a pipeline that is mostly pre-clinical (behind Markers).
Then Cellectis with a market cap of 800+ million and a pipeline that is mostly pre-clinical (behind Markers).
And consider the many billions that KITE and JUNO got bought out for.
Markers 240 million market cap seems awful cheap to me considering their MultiTAA potential and their pipeline.
Comments (gleaned info) about/from March 28 biz update.
It was said that about one month from March 28 (about now), MRKR was having a FDA meeting concerning Pre-IND (investigational new drug) application, and with post transplant AML there was virtually no other available therapy so for those in the study who do not get the MRKR therapy, they would get "standard of care" which would be nothing more than "observation", in other words "nothing".
If that is the case, then efficacy or positive results compared to "observation" or "nothing" should be a pretty easy endpoint to beat by a mile I would think.
Concerning the pancreatic trial info that was going to be presented at ASCO, two observations.
First, even though there are 30 patients enrolled, at ASCO they only would have presented data from just a few patients because the patients have to progress along timewise before they can have any meaningful data to present, ie: six rounds of chemo or whatever, so it may just be better off that they missed ASCO and present/release that data in a few months when they have a larger patient base to report on.
Also, something was said in a round about way that I think was telling.
It was asked, why the pancreatic patients increased so quickly over a short period of time from December.
Although it was really not answered directly, it was said that MultiTAA is not as well known as CAR-T (bad for now), but it was also said that patients and clinicians (Doctors) tend to be well read and informed and when they get a hint or whiff of efficacy or success, they gravitate toward that efficacy.
So it would seem that there was a whiff of success in the MRKR pancreatic trial that got out to clinicians (good).
One more bit of info that was said about solid tumors and other cancers.
For CAR-T and other non-MRKR therapies, it can take a year or more and a lot of money to develop a new approach or let's say a new medicine to start a trial for.
MRKR said that although for Multi-TAA it might take a month, for solid tumors and other cancers it would take MRKR NO TIME AT ALL because all the pre-clinical work has ALREADY BEEN DONE to add several more peptide antigens to their current therapy, and they can add/increase from five up to eleven antigens to expand their target repertoire for other possible cancer targets, and they said they can "do that today if they choose to".
So having said all of that, WHY are there 4 million shares shorted ???
https://www.markertherapeutics.com/wp-content/uploads/2019/03/MarkerTherapeutics_20190328_500PME.mp3
When I think of all these shorts, I am reminded of a song from 1963 released by RUBY & THE ROMANTICS.
OUR DAY WILL COME … and then the shorts will be screwed.
Shorts up to over 4 million shares.
When they all have to cover it will be funny.
Remember, 3 million of those shares were shorted under $7.
MRKR - killer Multi-TAA technology.
1/10th the cost of Car-T in 1/4 the timeframe.
300 million market cap sitting on 10 - 12 billion tech when you consider what Juno and Kite got bought out at.
MRKR - killer Multi-TAA technology.
1/10th the cost of Car-T in 1/4 the timeframe.
300 million market cap sitting on 10 - 12 billion tech when you consider what Juno and Kite got bought out at.
Yeah, I guess it was good for Moleculin.
It just upsets me because we (MRKR) have very good success with several diseases in HUMANS …. nothing.
They have a success with a mouse …. and the stock triples.
There is definitely a lot SELLING pressure and not much BUYING pressure.
Why do I say that.
I've been short term trading in nice round numbers, ie: 1000 or 2000 shares per each order.
When I BUY (which means others are selling), it is done in one trade, 1000 shares per order.
BUT, when I SELL (which needs others to buy), it takes numerous trades like this:
Filled Sell 16 MRKR Limit 5.57 10:14:56 04/22/19
Filled Sell 218 MRKR Limit 5.57 10:14:56 04/22/19
Filled Sell 100 MRKR Limit 5.57 10:14:56 04/22/19
Filled Sell 50 MRKR Limit 5.57 10:14:56 04/22/19
Filled Sell 196 MRKR Limit 5.57 10:14:56 04/22/19
Filled Sell 420 MRKR Limit 5.57 10:14:56 04/22/19
BUT THE BUYS:
Filled Buy 1000 MRKR Limit 5.07 09:51:54 04/23/19
There is just no buying pressure from individuals or institutions.
You would THINK that at least institutions would be loading up at these cheap prices????
I just DO NOT understand it.
So just for yucks, I just tripled down on my OTA (one triggers another) orders, so instead of 2 open OTA's, I got 6 open OTA's, varying price ranges, 5.07-5.57, 5.05-5.60, 4.75-5.45.
Feel free to play along.
Can someone explain how this is legal?
OK, Last Wednesday 4-17, Moleculin Announces Significant Discovery in Lung Cancer Models (very early mouse models), and the next day 4-18, Moleculin Biotech Gets FDA Fast Track Designation for Annamycin.
Stock goes from $1.00 to $1.40 - OK that makes sense.
THEN, yesterday, Moleculin Announces Conference Call to Discuss Significant Discovery For Lung Cancer and FDA Activity on Wednesday, April 24, 2019.
NOW, the conference call (tomorrow) will discuss WHAT THEY ALREADY ANNOUNCED on 4-17 and 4-18.
And yesterday. for some idiotic reason, the stocks goes up to past $3.00 … because of 2 reasons, #1 people who thought this was NEW news and didn't realize they already announced it last week, and #2 momentum players, the trend is your friend.
Today, stock dumps back down to 1.59.
OK, NOW, here is the part I question the legality of.
TODAY, Moleculin Announces $15.0 Million Registered Direct Offering, of 9,375,000 units at a public offering price of $1.60 per unit in a registered direct offering. Each unit is comprised of one share of common stock and 0.5 of a warrant to purchase one share of common stock.
HOW is it legal for the company ITSELF to artificially raise the stock price with a bogus announcement that they ALREADY made several days before and then take advantage of that higher price in order to have a stock offering at a price higher than the stock would have otherwise been?
It seems to me that the stock offering was planned before hand, they made their FIRST announcements on 4-17 and 4-18, but the stock did not go as high as they hoped, so they make a second bogus announcement to drive the stock price higher. How is that legal?
Sold them yesterday at 5.57, bought them all back this morning at 5.07.
Next order, sell them at 5.57.
Rinse and repeat (just the "trade" shares), not the long term hold shares.
$1000+ here, $1000+ there, they're playing the game, why not play along and make extra $'s.
Follow up to post 26200. The recently bought shares, sold this morning at 5.57. Next order, buy them back at 5.07.
Rinse and repeat, if THEY are playing the low 5's to low 6's game, I might as well just play along.
Sounds good to me - “With promising early clinical results in multiple cancer indications, we believe our therapies may represent the next major leap forward in cell therapy for cancer,” said Peter L. Hoang, President and CEO of Marker Therapeutics.
This just started in March 2019 when OutcomeRx and Vineti announced a new alliance to build patient-centered digital and services solutions to streamline cell and gene therapies.
One month later, Marker taking advantage of it, GREAT. If it helps us do trials faster, better, more efficiently, and produces better results, sounds good to me.
Phase 2 trial with the Mayo Clinic.
Phase 2 trial with Memorial Sloan Kettering.
Phase 2 trial with Baylor College of Medicine.
A (seemingly) promising Phase 1/2 Baylor trial (pancreatic cancer).
A Nobel prize winner.
Backers with good track records like NEA and Baker.
Yeah, this company sucks.
I guess maybe when we also have trials with M D Anderson and St. Jude we will get noticed.
Wish there was more buying for accumulation. Today's very light 220,000 shares volume I would have thought would be MUCH heavier volume given that the price is near the lows.
One can't really say it is because there are no shares being offered to sell … because …
the shares I bought yesterday at 5.05, I've got an open sell limit 5.60, the price has been up to 5.56 today, so if there was any serious accumulation at these low bargain prices, surely someone accumulating would be willing to pay 5.60 if they were willing to pay 5.56.
OK Thanks, waiting on AACR in July and ESMO in September.
Still trading on the side in the meantime though.
That is EXACTLY what I'm upset about.
If there is only one thing a cancer company does NOT want to screw up, it is the only one shot per year ASCO meeting.
"The abstract was submitted under the TIP (Trials in Progress) track. Abstracts submitted under the TIP track cannot include new clinical data. They can only reference data that has already been presented."
THEY SHOULD HAVE KNOWN THAT and submitted it the correct way under the correct category.
OK Phantom, Thanks again. I just think that they (whoever) should have either presented the abstract in a form that would have been accepted, OR they should have know because of ASCO regs that what they wanted to present WOULD be rejected in advance and not put all of us through this hoping on ASCO game.
Phantom, this low 5's to low 6's stock price, back and forth tennis game that MRKR has been playing for MANY MONTHS is now going to continue.
The shares I bought this morning at 5.05 ...
Now, let me stop for a second and say:
I am NOT selling any shares I owned yesterday that are long term holds,
And I'm NOT suggesting that anybody sell their own long term hold shares,
BUT, the shares I bought this morning at 5.05, I'm not even waiting for $6+. I just put in another OTA (one triggers another) order:
Sell (this mornings bought shares) limit $5.60, then
Buy (the same amount) limit $5.10.
And I am going to jump in with the Market Makers and ride along and play their game, over and over and over, as many times as it works.
Still holding my long term shares, but if I can make an extra $1000+ over and over while I wait for the hoped for great news, I'll just trade playing whatever game whoever is playing with this up and down (like clockwork) stock price oscillations.
It kind of sucks that we have to rely on an investor (YOU) to get accurate news instead of the company where it is supposed to be coming from.
This has been a pattern for years and it's getting kind of old.
Would like Phantom to give an update and opinion on todays events … as my plan backfired.
I had an OTA (one triggers another) order to buy at 5.27, which would trigger the next order to buy at 5.05.
Well, both orders got executed at 5.05 at the open this morning.
Both orders being filled at 5.05 was good, that's not the backfire part.
I was hoping to buy more cheap before the news that we were accepted for ASCO, which would (I hoped) raise the share price.
Oh well, that didn't work out.
This company, SERIOUSLY, has to tell us what is happening, news/presentations/results wise, and when for the next several months.
Nothing for nothing, but if we don't hear meaningful news, as soon as MRKR hits $6.00>, I'm selling what I just bought this morning as 5.05.
I already had too much before this mornings buy.
ASGCT - American Society of Gene & Cell Therapy - April 29 - May 2
ASCO - American Society of Clinical Oncology - May 31 – June 4
Don't know what is being presented where, but we're supposed to know about ASCO tomorrow.
I hope we present at BOTH meetings.
Besides the original TPIV shares I owned for many years, in the past 12 months bought more at 7.07, 6.58, 6.06, 5.57, and 5.05. Already own way more than I originally intended to (even after the merger news). I don't want to help push it down, but I always try to get it cheaper than last time. I REALLY don't think we will see below 5.05 again (I HOPE), but if I can't get more in the low 5's, I'll stick with current holdings.
Even though I bought more in early Feb. at 5.05 and normally wouldn't buy more unless the price was a good deal lower, just in case it drops more from here before news, I got in buy at 5.27. We'll see.
OooKkk?
On 12-31-18, 1.1 million shares were shorted … and we were selling at $7.20.
Now there are 3 million shares shorted (almost 3 times the amount) … and we have traded BELOW $7.20 the Entire Time.
So, there is no doubt that almost 2 million shares were shorted BETWEEN $6 and $7.
One little tiny bit of good news, any tiny tidbit that makes it pop to $8, is just going to blow 2 million shorts right out of the water.
Any price above $7.20, and they are losing money.
Geez, if that were me, and I had that small of a price margin before I was losing money, I'd be Very Nervous.
I'm sure they already have their orders in to cover at just below their loss price, around $6.50, or whatever it needs to be.
I also think that, SINCE 12-31-18, EVERY TIME the price has started to creep up to their $6.50 (or whatever) cover price, They have been supporting their cover price by Shorting More.
This WILL backfire on them.
No Doubt, at some point, (and I think one tiny bit of good news soon some point), THIS WILL BACKFIRE ON THEM.
When I first read about 4-15 lockup, I asked, who, what owners would sell? And then who, what owners would sell at $6.
I could see some selling if we were at $20, profit taking for safety, or someone wants to buy a new car or home, etc.
And even if there was selling, you would think that Vanguard or T Rowe Price or Janus would be there to snap up any sold shares.
I guess we will see in the next couple of weeks.
I'm just waiting on ASCO developments.
Thanks PL for info/insight/calmness.
Opinions? I've been reading everybody's posts from the last few days and there seems to be some new info (?).
If I understood correctly, in 10 days, on April 15th, a stock lockup period is over, so, in theory that may lead to selling? But, would that also be better over the medium/long term because it would put more shares out and MRKR would have more liquidity?
Anybody know about how many more shares will be liquid?
Also, read that in December we had 3 pancreatic patients, but now we have (at least) 30, but maybe as many as 45 (full enrollment).
Wouldn't that indicate that they must have had great success early on in order for so many additional patients to be enrolled in such a short period of time?
I don't even know … are Doctors allowed to tell other Doctors about successes (before they are reported)?